Châtillon, France, November 4, 2025




DBV Technologies to Participate in the Guggenheim
2nd Annual Healthcare Innovation Conference

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market:
DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today
announced Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at
the Guggenheim 2nd Annual Healthcare Innovation Conference on Tuesday,
November 11, at 2:00 p.m. ET in Boston, Massachusetts.

A live webcast of the fireside chat be accessed here and will also be available on the
Events section of the Company’s Investors website: https://dbv-
technologies.com/investor-overview/events/, with an archived replay accessible for
90 days following the event.

About DBV Technologies
DBV Technologies is a clinical-stage biopharmaceutical company developing
treatment options for food allergies and other immunologic conditions with
significant unmet medical need. DBV Technologies is currently focused on
investigating the use of its proprietary VIASKIN® patch technology to address food
allergies, which are caused by a hypersensitive immune reaction and characterized
by a range of symptoms varying in severity from mild to life-threatening
anaphylaxis. Millions of people live with food allergies, including young children.
Through epicutaneous immunotherapy (EPIT), the VIASKIN® patch is designed to
introduce microgram amounts of a biologically active compound to the immune
system through intact skin. EPIT is a new class of non-invasive treatment that seeks
to modify an individual’s underlying allergy by re-educating the immune system to
become desensitized to allergen by leveraging the skin’s immune tolerizing
properties. DBV Technologies is committed to transforming the care of food allergic
people. The Company’s food allergy programs include ongoing clinical trials of
VIASKIN Peanut in peanut allergic toddlers (1 through 3 years of age) and children
(4 through 7 years of age).

DBV Technologies is headquartered in Châtillon, France, with North American
operations in Warren, NJ. The Company’s ordinary shares are traded on segment B
of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company’s ADSs (each
representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT –
CUSIP: 23306J309).
For more information, please visit www.dbv-technologies.com and engage with us
on X (formerly Twitter) and LinkedIn.

VIASKIN is a registered trademark of DBV Technologies.

Investor Contact
Katie Matthews
DBV Technologies
katie.matthews@dbv-technologies.com

Media Contact
Brett Whelan
DBV Technologies
brett.whelan@dbv-technologies.com